SCHEDULE: Toronto-Dominion Bank Discloses 6.9% Stake in UroGen Pharma

The Toronto-Dominion Bank has reported a 6.9% beneficial ownership stake in UroGen Pharma Ltd., holding over 3.19 million ordinary shares.

Summary

• The Toronto-Dominion Bank has filed a Schedule 13G, indicating beneficial ownership of 3,190,510 ordinary shares of UroGen Pharma Ltd.
• This stake represents 6.9% of UroGen Pharma Ltd.'s outstanding ordinary shares.
• The beneficial ownership includes sole voting power and sole dispositive power over all 3,190,510 shares.
• The shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Beneficial ownership of the securities was transferred to The Toronto-Dominion Bank from Cowen Financial Products LLC, an affiliated entity, between the event date and the filing date.

Sentiment

Score: 5

Explanation: The filing is a factual report of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment by a major financial institution, The Toronto-Dominion Bank, in a pharmaceutical company. Such disclosures are common and provide transparency regarding large ownership stakes, which can signal institutional confidence or strategic positioning within the healthcare and biotechnology sectors.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and trading activity.

Key Dates

Keywords

UroGen Pharma, Toronto-Dominion Bank, Beneficial Ownership, Schedule 13G, Institutional Investor, Ordinary Shares, Equity Stake